EU regulator backs use of Novo's Wegovy for obesity-related heart condition
The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...
Novo’s Wegovy Backed by EU Regulator For Obesity-Related Heart Conditions. FDA Could Be Next.
Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.
STAT48m
Novo’s new obesity drug shows modest results, raises concerns of psychiatric side effects
A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...
devdiscourse50m
Novo Nordisk Faces Setback with Monlunabant Trial Results
Novo Nordisk's stock dropped by more than 4% following disappointing results from a Phase 2a trial of its obesity pill, Monlunabant. The experimental drug, acquired through Inversago Pharmaceuticals, ...
Novo Nordisk shares drop more than 4% on disappointing obesity pill data
Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from ...
FierceBiotech29m
Novo obesity prospect linked to ‘mild to moderate neuropsychiatric side effects’ in phase 2
In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...
Opinion
Montreal News18mOpinion
Brownstein: Scientist will give the skinny on Ozempic during symposium at McGill
Dr. Patricia Brubaker and Dr. Pieter Cohen are the speakers at this year’s Trottier Public Science Symposium, Monday at 7 p.m. at McGill University’s Leacock Building, Room 132. Admission is free, but ...